CO2024011229A2 - Síntesis de inhibidores de tirosina quinasa de bruton - Google Patents

Síntesis de inhibidores de tirosina quinasa de bruton

Info

Publication number
CO2024011229A2
CO2024011229A2 CONC2024/0011229A CO2024011229A CO2024011229A2 CO 2024011229 A2 CO2024011229 A2 CO 2024011229A2 CO 2024011229 A CO2024011229 A CO 2024011229A CO 2024011229 A2 CO2024011229 A2 CO 2024011229A2
Authority
CO
Colombia
Prior art keywords
synthesis
tyrosine kinase
kinase inhibitors
bruton tyrosine
formula
Prior art date
Application number
CONC2024/0011229A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Fernandes
William Marc Maton
Christos Xiouras
Ngoc Duc Tran
Edward Cleator
Thomas Joachim Landewald Rammeloo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2024011229A2 publication Critical patent/CO2024011229A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CONC2024/0011229A 2022-02-18 2024-08-20 Síntesis de inhibidores de tirosina quinasa de bruton CO2024011229A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GR20220100151 2022-02-18
EP22167032 2022-04-06
EP22178413 2022-06-10
PCT/EP2023/054043 WO2023156599A1 (en) 2022-02-18 2023-02-17 Synthesis of bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
CO2024011229A2 true CO2024011229A2 (es) 2024-08-30

Family

ID=85227338

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0011229A CO2024011229A2 (es) 2022-02-18 2024-08-20 Síntesis de inhibidores de tirosina quinasa de bruton

Country Status (13)

Country Link
US (1) US20250163076A1 (https=)
EP (1) EP4479405A1 (https=)
JP (1) JP2025506671A (https=)
KR (1) KR20240148351A (https=)
AU (1) AU2023221549A1 (https=)
CA (1) CA3252338A1 (https=)
CL (1) CL2024002409A1 (https=)
CO (1) CO2024011229A2 (https=)
IL (1) IL314902A (https=)
JO (1) JOP20240182A1 (https=)
MX (1) MX2024010134A (https=)
PE (1) PE20242069A1 (https=)
WO (1) WO2023156599A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025262118A1 (en) * 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
MX2024010134A (es) 2024-08-27
CA3252338A1 (en) 2023-08-24
KR20240148351A (ko) 2024-10-11
EP4479405A1 (en) 2024-12-25
IL314902A (en) 2024-10-01
PE20242069A1 (es) 2024-10-18
JP2025506671A (ja) 2025-03-13
JOP20240182A1 (ar) 2024-08-14
US20250163076A1 (en) 2025-05-22
WO2023156599A1 (en) 2023-08-24
AU2023221549A1 (en) 2024-10-03
CL2024002409A1 (es) 2025-01-03

Similar Documents

Publication Publication Date Title
BR112023017661A2 (pt) Inibidores de kras
AR121483A1 (es) Hidrato cristalino de un compuesto inhibidor de jak
MX2013002461A (es) Compuestos y composiciones novedosos para la inhibición de nampt.
EA201000113A1 (ru) Пиразольные соединения
PE20220430A1 (es) PROCESO PARA LA SINTESIS DE 4-({2-[(AMINOSULFONIL)AMINO]ETIL}AMINO)-N-(3-BROMO-4-FLUOROFENILl)-N'-HIDROXI-1,2,5-OXADIAZOL-3-CARBOXIMIDAMIDA UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA
CO2024011229A2 (es) Síntesis de inhibidores de tirosina quinasa de bruton
CL2024002895A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2025012180A (es) Sintesis de inhibidores de ras
CO2025018750A2 (es) Inhibidores de wrn
CO2021000940A2 (es) Procedimiento y productos intermedios para la preparación de bilastina
UY40657A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
IL314221A (en) Synthesis of a kif18a inhibitor
CL2025002125A1 (es) Compuestos novedosos
BR112022012149A2 (pt) Síntese de compostos para promover o crescimento do cabelo
MX2023013179A (es) Metodos para elaborar un modulador de hemoglobina.
CL2023001018A1 (es) Compuestos inhibidores de autotaxina
MX2024009581A (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1.
MX2025007840A (es) Formas de estado sólido de inhibidores de mnk
MX2025000791A (es) Compuestos terapeuticos, formulaciones y uso de los mismos
MX2022010675A (es) Composiciones que comprenden profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos.
EA202092114A1 (ru) Новый способ получения спрингена
MX2021006499A (es) Proceso de preparacion de un enol eter biciclico.
CL2023003823A1 (es) Método para preparar inhibidor de xantina oxidasa
AR132901A1 (es) Inhibidores de wrn